MeiraGTx (NASDAQ:MGTX) Given Buy Rating at Chardan Capital

Chardan Capital reissued their buy rating on shares of MeiraGTx (NASDAQ:MGTX) in a report issued on Monday morning,Benzinga reports. They currently have a $36.00 target price on the stock.

Separately, Royal Bank of Canada upped their target price on shares of MeiraGTx from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th.

MeiraGTx Trading Down 2.7 %

Shares of MeiraGTx stock opened at $5.82 on Monday. MeiraGTx has a fifty-two week low of $3.85 and a fifty-two week high of $7.60. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.34 and a current ratio of 2.34. The firm has a market capitalization of $454.83 million, a price-to-earnings ratio of -4.81 and a beta of 1.24. The stock has a 50 day moving average of $5.24 and a 200 day moving average of $4.82.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Knoll Capital Management LLC acquired a new stake in shares of MeiraGTx in the third quarter valued at $5,212,000. Erste Asset Management GmbH acquired a new position in MeiraGTx in the 3rd quarter valued at about $2,795,000. Garden State Investment Advisory Services LLC purchased a new stake in MeiraGTx during the third quarter worth about $1,636,000. Privium Fund Management B.V. lifted its position in shares of MeiraGTx by 70.0% during the second quarter. Privium Fund Management B.V. now owns 203,960 shares of the company’s stock worth $804,000 after purchasing an additional 83,975 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of MeiraGTx by 107.1% in the third quarter. Barclays PLC now owns 147,827 shares of the company’s stock valued at $618,000 after purchasing an additional 76,437 shares during the period. 67.48% of the stock is currently owned by institutional investors and hedge funds.

MeiraGTx Company Profile

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.